Serdexmetylfenidát

Serdexmethylphenidate is a prodrug of dexmethylphenidate designed to provide extended therapeutic effects with reduced abuse potential through delayed onset. FDA-approved in 2021 as part of Azstarys for ADHD treatment in patients 6 years and older. The substance is metabolized in the lower gastrointestinal tract to release dexmethylphenidate gradually. Schedule IV controlled substance in the United States. Not recommended for patients with structural cardiac abnormalities, serious heart disease, or within 14 days of MAOI use.

Also known as: Sdx, Kp415, Azstarys, Azstarys SDX component

Classification

Chemical: Phenidate
Psychoactive: Stimulant
Tag: Prodrug

Effects

Stimulation
Fatigue
Loss Of Appetite
Insomnia
Increased Heart Rate
Physical Euphoria
Focus Enhancement
Motivation Enhancement
Wakefulness
Cognitive Euphoria
Time Distortion
Analysis Enhancement
Appetite Suppression
Light Sensitivity
Increased Libido
Dehydration
Increased Sexuality
Increased Music Appreciation

Routes of Administration

Oral

Dosage

Light: 26.1 mg
Common: One capsule once daily: 26.1/5.2 mg to 52.3/10.4 mg (SDX/d-MPH HCl)
Strong: 52.3 mg
Threshold: Not established for SDX alone mg

Duration

Onset: 1-2 h
Comeup: 2-3 h
Peak: 4-8 h
Offset: 8-14 h
After Effects: 0-4 h
Total Duration: 10-14 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

dose.wiki

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu